DOAC reversal agents work but what comes next needs more data

The risk of death after severe DOAC-related bleeding remains significant despite a high rate of effective haemostasis with reversal agents. That’s the conclusion from a systematic review and meta-analysis of the evidence for clinical outcomes following bleeding and use of 4-factor prothrombin complex concentrates (4PCC) or specific reversal agents idarucizumab and andexanet alfa. The meta-analysis, ...

Already a member?

Login to keep reading.

© 2021 the limbic